Account
Articles
09.06.2023
What is a fair value for oncology combination pric...

We explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...

Read more
Insider Insights
04.05.2023
NICE collaborates with international partner agenc...

UK, Canada and United States join forces to streamline process and increase transparency for confide...

Read more
Case Study
26.04.2023
Undertaking a NICE advice procedure

Our client had concerns as to whether the clinical end-points in their phase III trial were relevant...

Read more
News
15.03.2023
PMA Insights: Week 11

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
22.02.2023
NICE announces the development of a new rapid revi...

New process to assess clinical and cost-effectiveness of COVID-19 treatments to get these medicines ...

Read more
Insider Insights
17.02.2023
Spain’s Ministry of Health copies NICE, and ...

Spain will ask pharmaceutical companies to submit their economic evaluation studies to reviewed late...

Read more
Insider Insights
25.01.2023
AstraZeneca/Daiichi Sankyo’s Enhertu has been re...

NICE have recommended Enhertu for the treatment of HER2-positive breast cancer within a managed acce...

Read more
Case Study
01.01.2023
Securing reimbursement for an orphan drug via NICE

Our client was seeking NICE approval for their ultra-orphan drug in an indication that was not well ...

Read more
News
16.11.2022
PMA Insights: Week 46 SPECIAL EDITION ISPOR 2022 R...

We summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...

Read more
Insider Insights
18.10.2022
UK Agencies join with International HTA Partners f...

A cross-border alliance of health technology assessment (HTA) agencies has been announced by the Can...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.